Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain.

SARS CoV-2 antibody assays measure antibodies against the viral nucleoprotein (NP) or spike protein. The study examined if testing of antibodies against both antigens increases the diagnostic sensitivity. Sera (N=98) from infected individuals were tested with ELISAs based on the NP, receptor-binding domain (RBD), or both proteins. The AUROCs were 0.958 (NP), 0.991 (RBD), and 0.992 (NP/RBD). The RBD- and NP/RBD-based ELISAs showed better performance than the NP-based assay. Simultaneous testing for antibodies against NP and RBD increased the number of true and false positives. If maximum diagnostic sensitivity is required, the NP/RBD-based ELISA is preferable. Otherwise, the RBD-based ELISA is sufficient. © 2021. The Author(s).

Citation

Nina Reiners, Carolin Schnurra, Henning Trawinski, Judith Kannenberg, Thomas Hermsdorf, Andrea Aebischer, Torsten Schöneberg, Sven Reiche, Christian Jassoy. Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2021 Dec;40(12):2645-2649

Mesh Tags

Substances

PMID: 34085159

search → result